Anna Lindholm Olinder
Biographic Data
| ID | 7606350 |
|---|---|
| NAME | Anna Lindholm Olinder |
| GIVEN NAMES | Anna Lindholm |
| FAMILY NAME | Olinder |
| SIGNATURE | OLINDER A L |
| AFFILIATIONS | Karolinska Institutet |
| ORCID | 0000-0002-8422-2457 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences
Among prematurely born infants and newborns with chronic conditions, a respiratory syncytial virus (RSV) infection may cause (re-)admission and later respiratory complications. Therapeutic protection is possible with monthly injections of a specific monoclonal antibody, palivizumab, during RSV season. Standard care is giving up to five injections in clinic-based settings. Immunization at home could be an alternative to standard care for vulnerabl…
No prominent works on this page.
Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences
Among prematurely born infants and newborns with chronic conditions, a respiratory syncytial virus (RSV) infection may cause (re-)admission and later respiratory complications. Therapeutic protection is possible with monthly injections of a specific monoclonal antibody, palivizumab, during RSV season. Standard care is giving up to five injections in clinic-based settings. Immunization at home could be an alternative to standard care for vulnerabl…
Adverse effect (1 work) · Antibody (1 work) · Environmental health (1 work) · Immunization (1 work) · Immunology (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Neonatal Respiratory Health Research (1 work) · Palivizumab (1 work) · Pediatrics (1 work)